Quantcast

Latest H5N1 clinical trials Stories

2009-11-11 13:00:00

SWIFTWATER, Pa., Nov. 11 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the final analyses of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults and children. To view the Multimedia News Release, go to: http://multivu.prnewswire.com/mnr/sanofi_pasteur/41122/ The data confirm the immunogenicity and safety profile of the vaccine, with no serious...

2009-11-11 09:30:00

ROCKVILLE, Md., Nov. 11 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances, will be presenting at the Influenza Congress USA 2009. Mr. Trizzino's presentation will take place at 3:30 pm local time on November 20, 2009 at The Westin Washington, Washington D.C. Mr. Trizzino will be discussing regional partnership drivers, benefits of regional partnerships...

2009-11-10 07:00:00

ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) has begun a Phase IIa clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older. This randomized, double-blind, active-controlled study is evaluating the safety, tolerability and immunogenicity of two different doses of Novavax's trivalent seasonal influenza VLP vaccine compared with that of a commercially available trivalent inactivated vaccine (TIV,...

2009-11-05 06:53:00

GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will...

2009-11-03 14:08:36

Pivotal testing of RTS,S is on track for target enrollment of 16,000 children A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria...

2009-11-02 07:00:00

ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine in Healthy Adults" on Saturday, October 31, 2009 at the 47(th) Annual Meeting of the Infectious Diseases Society of America (IDSA). This presentation included data from a study of Novavax's trivalent...

a572c7c0094dd102cdace4b01a2b02f71
2009-10-30 15:25:00

World Health Organization officials on Friday announced that one dose of the H1N1 swine flu vaccine is all that is needed to ensure immunity against the virus. The Strategic Advisory Group of Experts (SAGE) on Immunization devoted a session of its October 27-29 meeting to pandemic influenza vaccines. "Items on the agenda included the status of vaccine availability, results from clinical trials on vaccine immunogenicity, and early results from safety monitoring in countries where...

2009-10-22 14:30:00

GAITHERSBURG, Md., Oct. 22 /PRNewswire/ -- MedImmune announced today that interim data from human studies of its nasal spray vaccine for the 2009 novel Influenza A (H1N1) virus demonstrate a similar clinical profile in children and adults 2 to 49 years of age as previously studied seasonal formulations of the vaccine. The live attenuated influenza vaccine (LAIV) for the 2009 novel Influenza A (H1N1) virus received approval from the U.S. Food and Drug Administration (FDA) on September 15,...

2009-10-21 06:30:00

ROCKVILLE, Md. and MARLBOROUGH, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and Xcellerex, Inc. have entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process to commercial scale and begin immediate production of Novavax's novel 2009 H1N1 influenza vaccine for potential commercial sale. Earlier this week, Novavax launched a two-stage, 4,000-patient clinical study of its H1N1 flu vaccine in Mexico to support...

2009-10-20 03:30:00

ROCKVILLE, Md., Oct. 20 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related